Incite Health Statement on Governor Shapiro's Landmark Legislation Improving Health Outcomes for Pennsylvanians
25 Julio 2024 - 12:30PM
Business Wire
Biomarker testing advances clinical decision
making in precision medicine
Incite Health, Inc. applauds Governor Shapiro’s signing of House
Bill 1754 into law. This pivotal legislation will transform
healthcare for Pennsylvanians by mandating comprehensive biomarker
testing coverage by all state-regulated health plans, including
Medicaid, ensuring more residents will benefit from precision
medicine.
“Governor Shapiro’s commitment to healthcare innovation and
patient advocacy is evident in this landmark decision,” said Renold
J. Capocasale, Chief Executive Officer of Incite Health. “By
enabling wider access to biomarker testing, we are paving the way
for targeted treatments that not only improve survival rates and
quality of life but can also reduce healthcare costs for patients
facing serious illnesses such as cancer or other chronic
diseases.”
The importance of biomarker testing in modern healthcare cannot
be overstated. It facilitates personalized care by matching
patients with the most effective treatments and at the right dose
based on their unique genetic makeup. Despite its proven benefits,
insurance coverage for biomarker testing has lagged, often leaving
patients with the difficult choice of paying out-of-pocket or
forgoing potentially life-saving testing. House Bill 1754 addresses
these disparities, particularly benefiting communities of color,
lower-income individuals, and rural populations who have been
disproportionately affected by limited access.
“The PA Biotech Center plays a crucial role in our region,” said
PA State Senator Steve Santarsiero. He added, “Significant
advancements are consistently emerging from this center, Incite
Health, and the innovative work they are doing is a perfect
example. Their work will significantly improve healthcare. I am
pleased to have backed legislation that ensures medical coverage
keeps pace with this technological advancement, ultimately
enhancing the quality of life for many.”
Donna Greco, Government Relations Director for the American
Cancer Society Cancer Action Network (ACS CAN) in Pennsylvania,
praised the legislation, stating, “With his signature, Governor
Shapiro has delivered hope to countless Pennsylvanians who will
benefit from biomarker testing. This game-changing bill is good for
Pennsylvania, the health of our state and its residents.”
Christopher Molineaux, President and Chief Executive Officer of
LSPA said, “As the state association that represents organizations
involved in creating precision medicines and diagnostics, and the
patient advocacy groups those entities serve, this legislation was
of great interest. Life Sciences PA was proud to be part of the
Pennsylvania Biomarker Testing Coalition and to support the
legislation that expands access to biomarker testing to help
determine the treatment most effective for a specific patient.”
Incite Health remains dedicated to advancing healthcare access
and delivering healthcare innovation. We believe that the
implementation of House Bill 1754 will not only improve health
outcomes but also set a new standard for patient care in
Pennsylvania and beyond. For more information on precision medicine
and biomarker testing, visit www.fightcancer.org/biomarkers and
https://incitehealth.com/pharmacogenomics-testing/
About Incite Health:
Incite Health is a leading CLIA-certified, CAP-accredited high
complexity laboratory dedicated to revolutionizing clinical
decision making and enhancing patient care through innovative
medical practices and technologies. The company offers diagnostics,
precision medicine solutions and consultative services to improve
health outcomes and quality of life for all patients. Incite Health
clients include Pharmaceutical & Biotech clinical trial
sponsors, Contract Research Organizations, Health Care
Professionals, Long Term Care Facilities and privately insured
employers.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240725322477/en/
Media Contact: Ren Capocasale Founder & Chief
Executive Officer Incite Health, Inc 856-745-5045
RCapocasale@incitehealth.com